Kasra Shakeri-Nejad received his MD from the Charité, Faculty of Medicine of the Humboldt University Berlin and completed his Doctoral Thesis at the Charité Berlin in the Department of Neurosurgery. He received his advanced medical training in Neurology and holds a board certification as Medical Expert in Clinical Pharmacology.
He has 23 years of experience in clinical drug development with primary focus on neuropsychiatric disorders in different roles in the biopharmaceutical industry and as a principal investigator in CROs.
Kasra joined Novartis as a TME in Neuroscience in 2011 and has led the development of many neuroscience drugs at Novartis. He was responsible for the Clinical Pharmacology components of the development and the successful NDA submission and market launch of Mayzent (siponimod) in MS.
Since February 2022 Kasra is leading Translational Medicine Clinical Pharmacology, a cross-functional team which is specialized in the design, clinical execution and reporting of First-in-Human (FiH) and Clinical Pharmacology studies across all TM therapeutic areas.